Preoperative assessment of chemotherapeutic associated liver injury based on indocyanine green retention test.
BACKGROUND
The aim of the study was to assess the capacity of indocyanine green retention test at 15 min (ICGR15) to predict chemotherapeutic-associated liver injuries (CALI).


METHODS
Patients undergoing liver resection for CLM that received preoperative oxaliplatin and/or irintecan-based chemotherapy within 3 months before surgery and scheduled first hepatectomy were considered.


RESULTS
166 out of 983 patients treated between 01/2001 and 04/2014 fulfilled the inclusion criteria. The median number of cycles of preoperative chemotherapy was 6.0 ± 4.87. Chemotherapy was mainly based on oxaliplatin in 123 (74.1%). Bevacizumab was associated in 51(31%) patients. A total of 102 (61.4%) patients had at least 1 CALI. Grade 2-3 steatosis occurred in 56 (33.7%) patients and steatohepatitis in19(11.5%). Sinusoidal obstructive syndrome (SOS) was presented in 93 (56%) patients. 23(13.8%) patients had nodular regeneration hyperplasia. At multivariate analysis the only predictive factor of ICGR≥10% was age≥65 years (p = 0.001). A median split (ICGR15 = 8%) was used to categorized ICGR15 value. Multivariate analysis showed that age≥ 65 [OR 2.530 (CI95% 1.28-4.97) p < 0.001], male sex [OR 2.614 (CI95% 1.31-5.20) p < 0.001], SOS [OR 1.954 (CI95% 1.00-3.81) p = 0.050] and administration of Bevacizumab [OR 2.201 (CI95% 1.07-4.50) p = 0.031] were predictive factors for ICGR≥8%.


CONCLUSIONS
ICGR15 test can predict the diagnosis of SOS. High ICGR15 value is more common in elderly male patients and after bevacizumab administration.
Ospedale Mauriziano "Umberto I", Department of General and Oncologic Surgery, Turin, Italy. Electronic address: nrussolillo@mauriziano.it.
Nadia
N
Russolillo
Ospedale Mauriziano "Umberto I", Department of General and Oncologic Surgery, Turin, Italy. Electronic address: slangella@mauriziano.it.
Serena
S
Langella
Ospedale Mauriziano "Umberto I", Department of General and Oncologic Surgery, Turin, Italy.
Serena
S
Perotti
Ospedale Mauriziano "Umberto I", Department of General and Oncologic Surgery, Turin, Italy. Electronic address: rlotesoriere@mauriziano.it.
Roberto
R
Lo Tesoriere
Ospedale Mauriziano "Umberto I", Department of General and Oncologic Surgery, Turin, Italy. Electronic address: fforchino@mauriziano.it.
Fabio
F
Forchino
Ospedale Mauriziano "Umberto I", Department of General and Oncologic Surgery, Turin, Italy. Electronic address: aferrero@mauriziano.it.
Alessandro
A
Ferrero
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab / Q000009:adverse effects / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000000981:diagnostic imaging*; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D004396:Coloring Agents; D005234:Fatty Liver / Q000139:chemically induced / Q000000981:diagnostic imaging; D005260:Female; D006498:Hepatectomy; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced / Q000000981:diagnostic imaging; D006801:Humans; D007208:Indocyanine Green; D008099:Liver / Q000000981:diagnostic imaging / Q000187:drug effects / Q000601:surgery; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin
D000970:Antineoplastic Agents; D004396:Coloring Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab; D007208:Indocyanine Green
Chemotherapeutic-associated liver injuries; Indocyanine green retention test; Sinusoidal obstructive syndrome